Compare IPSC & ISD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPSC | ISD |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.5M | 412.5M |
| IPO Year | 2021 | N/A |
| Metric | IPSC | ISD |
|---|---|---|
| Price | $2.12 | $12.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.25 | N/A |
| AVG Volume (30 Days) | ★ 452.3K | 140.6K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.69% |
| EPS Growth | ★ 91.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,164,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1556.76 | N/A |
| 52 Week Low | $0.44 | $12.21 |
| 52 Week High | $2.97 | $14.79 |
| Indicator | IPSC | ISD |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 40.51 |
| Support Level | $1.88 | $12.26 |
| Resistance Level | $2.39 | $12.70 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 61.11 | 28.15 |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.